Analysis of the effect and feasibility of dapagliflozin in the treatment of elderly chronic heart failure
达格列净治疗老年慢性心力衰竭的效果及可行性分析

摘要

目的 分析在老年慢性心力衰竭中应用达格列净治疗的医学价值。方法 将2023年4月-2024年4月就诊的老年慢性心力衰竭患者80例分对照组常规抗心衰治疗，观察组40例增加达格列净，对比心脏各项指标、治疗后的活动耐力。结果 治疗前，指标对比差异不具有统计学意义（P>0.05），治疗后，观察组NT-proBNP高于对照组，LVED左室舒张末内径高于对照组，LVEA射血分数高于对照组，观察组的患者6min步行距离高于对照组，差异对比有统计学意义（P<0.05），结论 在老年慢性心力衰竭中应用达格列净治疗可改善心肌代谢，提高心功能，促活动耐力改善。

Abstract

Objective To analyze the medical value of using dapagliflozin in the treatment of elderly chronic heart failure.
Methods 80 elderly patients with chronic heart failure who received treatment from April 2023 to April 2024 were divided into a control group receiving routine anti heart failure treatment and an observation group receiving treatment with dapagliflozin. The cardiac indicators and activity endurance after treatment were compared.
Results Before treatment, there was no statistically significant difference in the comparison of indicators (P>0.05). After treatment, the observation group had higher NT proBNP than the control group, higher left ventricular end diastolic diameter in LVED than the control group, and higher ejection fraction in LVEA than the control group. The observation group had a higher 6-minute walking distance than the control group, and the difference was statistically significant (P<0.05).
Conclusion   The use of dapagliflozin in the treatment of elderly chronic heart failure can improve myocardial metabolism, enhance cardiac function, and improve activity endurance.